T1	Participants 116 147	patients with advanced melanoma
T2	Participants 570 737	Treatment-naïve or previously treated patients with unresectable stage III/IV melanoma (n = 115) received open-label ipilimumab (10 mg/kg every 3 weeks for four doses)
